Durvalumab and monalizumab for early bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs—durvalumab and monalizumab—for people with early-stage bladder cancer that hasn't spread into the muscle and has persisted or returned after BCG treatment. The goal is to see if this combination can control the cancer and delay or avoid the need for bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have non-muscle-invasive bladder cancer (cancer that hasn't spread into the muscle layer) that either came back or didn't fully go away after BCG treatment.
- You need to be unable to have or have decided not to have the bladder removal surgery (radical cystectomy).
- Any visible tumors must have been completely removed within the last 60 days (except flat tumors called CIS).
- Your blood counts, kidney and liver function must be within safe limits before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This trial tests a combination of an immunotherapy drug (toripalimab) with or without two chemotherapy drugs placed directly into the bladder (gemcitabine and mitomycin C). It is for people whose high-risk bladder cancer did not respond to or could not tolerate BCG treatment.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests whether bicalutamide can help men with non-muscle invasive bladder cancer (an early form that hasn’t spread into muscle). It is a Phase 1 study, meaning the main goal is to see how safe it is and learn how it behaves in the body for this cancer type.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.